Document is current
Any future updates will be listed below
-
Authors
Lin, Jia-Ren http://orcid.org/0000-0003-4702-7705
Chen, Yu-An
Campton, Daniel
Cooper, Jeremy
Coy, Shannon
Yapp, Clarence http://orcid.org/0000-0003-1144-5710
Tefft, Juliann B. http://orcid.org/0000-0002-8826-665X
McCarty, Erin
Ligon, Keith L. http://orcid.org/0000-0002-7733-600X
Rodig, Scott J.
Reese, Steven
George, Tad http://orcid.org/0000-0002-8123-0240
Santagata, Sandro http://orcid.org/0000-0002-7528-9668
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
- License Information
-
More Information
Article History
Received: 7 September 2022
Accepted: 8 May 2023
First Online: 22 June 2023
Competing interests
: P.K.S. is a cofounder and member of the Board of Directors of Glencoe Software, a member of the Board of Directors for Applied Biomath and a member of the Scientific Advisory Board for RareCyte, NanoString and Montai Health; he holds equity in Glencoe, Applied Biomath and RareCyte. P.K.S. is a consultant for Merck, and the Sorger lab has received research funding from Novartis and Merck in the past 5 years. Y.-A.C. is a consultant for RareCyte. D.C., J.C., E.M., S.R. and T.G. are employees of RareCyte. S.J.R. receives research support from Bristol Myers Squibb and KITE/Gilead. S.J.R. is on the Scientific Advisory Board for Immunitas Therapeutics. K.L.L. reports the following relationships: research support to DFCI from Bristol Myers Squibb and consulting fees from Bristol Myers Squibb, Integragen, Blaze Biosciences and Travera, Inc. K.L.L. is also an equity holder and Founder of Travera, Inc. The other authors declare no competing interests.
